BofA raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Buy rating on the shares. The firm is positive on the company’s decision to remain disciplined on the external growth front, but acknowledges the markets concern that it may fall behind as others shift to an offensive strategy.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: